Raymond James downgraded NeoGenomics from Outperform to Mkt Perform
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | Neutral | Guggenheim | |
| 4/30/2025 | $9.00 | Outperform → Market Perform | Leerink Partners |
| 1/13/2025 | Buy → Hold | The Benchmark Company | |
| 12/10/2024 | $22.00 | Buy | Jefferies |
| 5/1/2024 | $26.00 | Buy | Craig Hallum |
| 12/29/2023 | $25.00 → $21.00 | Buy | BTIG Research |
| 8/21/2023 | $18.00 | Equal-Weight → Overweight | Stephens |
| 5/16/2023 | Outperform → Mkt Perform | Raymond James |
Guggenheim initiated coverage of NeoGenomics with a rating of Neutral
Leerink Partners downgraded NeoGenomics from Outperform to Market Perform and set a new price target of $9.00
The Benchmark Company downgraded NeoGenomics from Buy to Hold
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic)
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians navigate complex treatment decisions more confidently. PanTracer Tissue evaluates over 500 cancer-related genes and aligns with clinical guidelines, covering key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment. Results may be delivered in as little as 8 days, enabli
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue a
8-K - NEOGENOMICS INC (0001077183) (Filer)
S-8 - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
3 - NEOGENOMICS INC (0001077183) (Issuer)
4/A - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic)
Consolidated Revenue Increased 8% to $168 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compared To First Quarter 2024 Consolidated revenue increased 8% to $168 million Net loss decreased 4% to $26 million Adjusted EBITDA increased 102% to positive $7 million "Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year," said Ton
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) o
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue a
Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)